Skip to main content

2010 New Drug Approvals - Pt. XII - Pegloticase (Krystexxa)


On September 14th 2010, the FDA approved Pegloticase under the trade name Krystexxa. Pegloticase is a recombinant enzyme for the treatment of gout and can replace xanthine oxidase (XO) inhibitors for patients who do not respond to or cannot tolerate treatment with xanthine oxidase inhibitors. 

Gout is a painful affliction caused by microscopic needle-shaped crystals of sodium urate which precipitate in joints and tendons and stimulate a local inflammatory response. These attacks of inflammatory arthritis not only cause pain and stiffness of the joint, but, if left untreated for years, also damage the cartilage and surrounding tissue. Hard, non-painful deposits of crystalline uric acid known as tophi occur in the joints and sometimes the kidney. 

Gout is generally associated with obesity, hypertension, insulin resistance and hyperlipidaemia. In more than half of the cases of diagnosed gout, patients have elevated blood levels of uric acid.

Conventionally, acute gout attacks are ameliorated by administration of non-steroidal anti-inflammatory drugs (NSAIDs) and the levels of uric acid are kept low by restricting diet, and also administration of inhibitors of xanthine oxidase (UniProt: P47989, ChEMBL: 149) such as allopurinol and febuxostat. Some patients however cannot tolerate conventional xanthine oxidase inhibitors because of severe allergic reactions. It is this group of patients that pegloticase has been approved for.

Pegloticase is a recombinant uricase, an enzyme that lowers the levels of puric acid by catalyzing the oxidation of puric acid to allantoin (see image), which in turn is readily eliminated via the kidneys. The uricase enzyme exists in all mammals but is not expressed in humans (Entrez Id of the pseudo-gene: 391051) and many primates. Therefore, pegloticase reduces uric acid levels through a catabolic function that has been relatively recently 'lost' in human evolution.

Pegloticase is a modified version of the mammalian uricase and is expressed in E.coli. Each uricase subunit is conjugated to monomethoxy-polyethylene-glycol (mPEG) and the enzyme occurs as a tetramer weighing ~540 kDa.

Eight milligram of Pegloticase are administered every two weeks as a parenteral infusion. In a single-dose, dose-ranging trial, Pegloticase reduced uric acid levels in a dose dependent manner and for doses of 8mg and 12mg, uric acid levels were kept below 6mg/dL for more than 300 hours (n=4).

Krystexxa comes with a boxed warning regarding anaphylaxis and infusion reactions as in clinical trials it caused anaphylaxis in 6.5% of patients treated with Krystexxa every 2 weeks and infusion reactions in 26% of these patients.

The sequence of Peglocitase is very similar to that of pig uricase (UniProt:P16164)

Pegloticase must not be given to patients suffering from glucose-6-phosphate dehydrogenase (G6PDH) deficiency as there is a risk of hemolysis and methaemoglobinemia.

Krystexxa is marketed by Savient Pharmaceuticals Inc., the full prescribing information can be found here.


Popular posts from this blog

UniChem 2.0

UniChem new beta interface and web services We are excited to announce that our UniChem beta site will become the default one on the 11th of May. The new system will allow us to better maintain UniChem and to bring new functionality in a more sustainable way. The current interface and web services will still be reachable for a period of time at . In addition to it, the most popular legacy REST endpoints will also remain implemented in the new web services: Some downtime is expected during the swap.  What's new? UniChem’s current API and web application is implemented with a framework version that’s not maintained and the cost of updating it surpasses the cost of rebuilding it. In order to improve stability, security, and support the implementation and fast delivery of new features, we have decided to revamp our user-facing systems using the latest version of widely used and maintained frameworks, i

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

ChEMBL 30 released

  We are pleased to announce the release of ChEMBL 30. This version of the database, prepared on 22/02/2022 contains: 2,786,911 compound records 2,157,379 compounds (of which 2,136,187 have mol files) 19,286,751 activities 1,458,215 assays 14,855 targets 84,092 documents Data can be downloaded from the ChEMBL FTP site: Please see ChEMBL_30 release notes for full details of all changes in this release: New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document ID CHEMBL4689842):   The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesize at least

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra